Smyth JF - Search Results

1

Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo.

Chirrey L, Cummings J, Halbert GW, Smyth JF. Chirrey L, et al. Among authors: smyth jf. Cancer Chemother Pharmacol. 1995;35(4):318-22. doi: 10.1007/BF00689451. Cancer Chemother Pharmacol. 1995. PMID: 7828274

2

Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase.

Spanswick VJ, Cummings J, Smyth JF. Spanswick VJ, et al. Among authors: smyth jf. Biochem Pharmacol. 1996 Jun 28;51(12):1623-30. doi: 10.1016/0006-2952(96)00104-9. Biochem Pharmacol. 1996. PMID: 8687477

3

Doxorubicin-loaded casein microspheres: protein nature of drug incorporation.

Willmott N, Magee GA, Cummings J, Halbert GW, Smyth JF. Willmott N, et al. Among authors: smyth jf. J Pharm Pharmacol. 1992 Jun;44(6):472-5. doi: 10.1111/j.2042-7158.1992.tb03649.x. J Pharm Pharmacol. 1992. PMID: 1359070

4

Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.

Willmott N, Cummings J, Marley E, Smyth JF. Willmott N, et al. Among authors: smyth jf. Biochem Pharmacol. 1990 Mar 15;39(6):1055-62. doi: 10.1016/0006-2952(90)90284-r. Biochem Pharmacol. 1990. PMID: 2322293

5

Determination of mitomycin C, 2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumour tissue by high-performance liquid chromatography.

Cummings J, Chirrey L, Willmott N, Halbert GW, Smyth JF. Cummings J, et al. Among authors: smyth jf. J Chromatogr. 1993 Jan 29;612(1):105-13. doi: 10.1016/0378-4347(93)80373-c. J Chromatogr. 1993. PMID: 8454690

6

Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition.

Cummings J, Willmott N, Marley E, Smyth J. Cummings J, et al. Biochem Pharmacol. 1991 Jun 15;41(12):1849-54. doi: 10.1016/0006-2952(91)90123-m. Biochem Pharmacol. 1991. PMID: 2039540

7

The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.

French RC, Cummings J, MacLellan A, MacPherson JS, Ritchie AA, Smyth JF. French RC, et al. Among authors: smyth jf. Cancer Chemother Pharmacol. 1993;32(2):156-61. doi: 10.1007/BF00685620. Cancer Chemother Pharmacol. 1993. PMID: 8485810

8

Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.

Cummings J, Spanswick VJ, Tomasz M, Smyth JF. Cummings J, et al. Among authors: smyth jf. Biochem Pharmacol. 1998 Aug 15;56(4):405-14. doi: 10.1016/s0006-2952(98)00073-2. Biochem Pharmacol. 1998. PMID: 9763215 Review.

9

Pharmacological determinants of the antitumour activity of mitomycin C.

Spanswick VJ, Cummings J, Ritchie AA, Smyth JF. Spanswick VJ, et al. Among authors: smyth jf. Biochem Pharmacol. 1998 Dec 1;56(11):1497-503. doi: 10.1016/s0006-2952(98)00164-6. Biochem Pharmacol. 1998. PMID: 9827584

10

The consequences of doxorubicin quinone reduction in vivo in tumour tissue.

Cummings J, Willmott N, Hoey BM, Marley ES, Smyth JF. Cummings J, et al. Among authors: smyth jf. Biochem Pharmacol. 1992 Dec 1;44(11):2165-74. doi: 10.1016/0006-2952(92)90343-h. Biochem Pharmacol. 1992. PMID: 1472081

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters